Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + weekly paclitaxel + bevacizumab for advanced non-squamous NSCLC with idiopathic interstitial pneumonia (IP002)
jRCTs061180046Phase 2Completed
- Sponsor
- Kobe City Medical Center General Hospital
- Start
- Jan 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, paclitaxel and bevacizumab in non-small cell lung cancer (NSCLC) and idiopathic interstitial pneumonia (IIP), sponsored by Kobe City Medical Center General Hospital. Primary endpoint: Response rate. Started Jan 2013; status: completed.
02
Drugs
carboplatinpaclitaxelbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)idiopathic interstitial pneumonia (IIP)
Beyond the preview
Go deeper on jRCTs061180046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180046.